Announcement PDF ASX Announcement 17 September 2020 ASX Market Announcements ASX Limited Level 4, North Tower, Rialto 525 Collins Street Melbourne VIC 3000 Receipt of Research & Development Tax Incentive Melbourne, Australia, 17 September 2020 - Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), is pleased to confirm the receipt of $615,000 under the Australian Government’s Research and Development (“ R&D” ) Tax Incentive Scheme. The claim covers the year ended 30 June 2019. The R&D Tax Incentive is an Australian Government program developed to assist businesses recover some of the costs of undertaking research and development. Under this program, companies receive cash refund for 43.5% of eligible expenditure on R&D. The receipt of these funds confirms the Company’s significant and ongoing commitment to develop and commercialise innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). For enquiries, please contact Ms Melanie Leydin Company Secretary Avecho Biotechnology Limited +61 3 9002 5000 This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited. About Avecho Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. See more here - avecho.com.au Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au